Predictive and Prognostic Value of p16 in Head and Neck Squamous Cell Carcinoma Patients Treated with Molecular Targeted Agents or Immune Checkpoint Inhibitors: Subgroup Analysis of the TRIUMPH Study. | Synapse
Predictive and Prognostic Value of p16 in Head and Neck Squamous Cell Carcinoma Patients Treated with Molecular Targeted Agents or Immune Checkpoint Inhibitors: Subgroup Analysis of the TRIUMPH Study.
To evaluate the prognostic and predictive role of p16 in patients with head and neck squamous cell carcinoma treated with specific therapies.
Subgroup analysis from the TRIUMPH study
Comparison of progression-free survival (PFS) and overall survival (OS) between p16 positive and negative patients
Assessment of treatment outcomes with molecular targeted agents and immune checkpoint inhibitors.
Patients with p16 (+) exhibited longer progression-free survival
Patients with p16 (+) demonstrated improved overall survival compared to p16 (-) patients.
Abstract
Patients with p16 (+) showed longer PFS and OS compared to p16 (-) patients. This suggests that p16 has prognostic and predictive values in HNSCC patients who are treated with MTAs or ICIs.